Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
J Dermatol ; 36(1): 35-44, 2009 Jan.
Article in English | MEDLINE | ID: mdl-19207435

ABSTRACT

Psoriasis constitutes one of the most representative examples of psychosomatic disorders. The published work investigating the psychological parameters and the way they interact during the course of the disease is extensive, whereas only a few studies have focused on the neuroendocrine framework of psoriasis. In the present study, the objective was to investigate the neuroendocrine parameters of psoriasis and the way they interact with psychopathological and immune variables. Patients with psoriasis (n=24) and the same number of matched healthy controls underwent psychiatric evaluation with interviews and psychometric questionnaires. Both of the groups underwent the corticotropin-releasing hormone (CRH) test and the dexamethasone suppression test (DST) to investigate functional parameters of the hypothalamus-pituitary-adrenal (HPA) axis. The evaluation of immune variables included the estimation of the distribution of T-cell and natural killer lymphocytes. Levels of depressive and anxiety features were increased within subjects with psoriasis and they were significantly correlated with stressful life events and the extent of the disease. The adrenocorticotrophic hormone and cortisol levels increased after CRH infusion without significant differences between the two groups and the psoriatic subjects' cortisol suppression after DST was within normal range, though relatively blunted. No significant correlations were identified among neuroendocrine, psychopathological and immune parameters. No particular neuroendocrine profile has been identified among psoriatic patients and the hypothesized interaction with psychopathological and immune parameters was not replicated. Nevertheless, it is still premature to exclude the possibility that a subtle latent alteration of the HPA axis function might exist, in psoriasis, either stemming from the psychopathology or from the disease per se.


Subject(s)
Neurosecretory Systems/physiopathology , Psoriasis/physiopathology , Adult , Case-Control Studies , Corticotropin-Releasing Hormone , Dexamethasone , Female , Humans , Hypothalamo-Hypophyseal System/physiopathology , Male , Middle Aged , Pituitary-Adrenal System/physiopathology , Psoriasis/classification , Psoriasis/immunology , Psoriasis/psychology , Psychometrics
2.
Endocr Relat Cancer ; 15(3): 693-700, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18586836

ABSTRACT

Primary aldosteronism (PA) and, in particular, its two commonest subtypes (i.e. idiopathic hyperaldosteronism (IHA) and aldosterone-producing adenoma (APA)) have been recognized as the most common cause of secondary hypertension. While 'conservative' medical treatment with aldosterone receptor antagonists is the therapeutic approach of choice in controlling blood pressure in patients with PA due to IHA, the more invasive (laparoscopic) adrenalectomy seems to be the most suitable therapy for patients with APA. In this review, we focus on the medical approach for the management of APA in cases where surgical excision of the adrenal is not possible.


Subject(s)
Adrenal Cortex Neoplasms/drug therapy , Adrenocortical Adenoma/drug therapy , Mineralocorticoid Receptor Antagonists/therapeutic use , Adrenal Cortex Neoplasms/complications , Adrenal Cortex Neoplasms/metabolism , Adrenal Cortex Neoplasms/surgery , Adrenalectomy , Adrenocortical Adenoma/complications , Adrenocortical Adenoma/metabolism , Adrenocortical Adenoma/surgery , Aldosterone/metabolism , Humans , Hyperaldosteronism/drug therapy , Hyperaldosteronism/etiology
3.
Hormones (Athens) ; 6(4): 314-20, 2007.
Article in English | MEDLINE | ID: mdl-18055422

ABSTRACT

OBJECTIVE: Psychocutaneous diseases constitute a large proportion of psychosomatic disorders, with psoriasis being one of the most typical cases. Though alteration of Hypothalamic-Pituitary-Adrenal (HPA) axis function has been suggested as underlying several psychiatric disorders and psychosomatic diseases, there is little evidence of reduced response of the HPA axis in psoriasis after psychosocially induced laboratory stress. The aim of the study was to investigate any alteration of the neuroendocrine profile of psoriatic patients. DESIGN: The psoriatic patients (n=24) and the same number of matched controls underwent a CRH test which consisted of 100 microg h-CRH IV infusion and drawing of blood samples at 0 min and at 15, 30 and 60 min post h-CRH for measurement of plasma ACTH and cortisol concentration. RESULTS: Mean plasma ACTH and cortisol levels in both groups increased during the 60-min CRH test without significant difference. The total secretion of plasma ACTH and serum cortisol estimated as Area Under the Curve did not show significant difference between the groups either. CONCLUSIONS: Contrary to previous studies no particular neuroendocrine profile of HPA axis responsiveness was identified in psoriatic patients.


Subject(s)
Adrenal Glands/physiopathology , Corticotropin-Releasing Hormone , Hypothalamus/physiopathology , Pituitary Gland/physiopathology , Psoriasis/physiopathology , Adrenocorticotropic Hormone/blood , Adult , Female , Humans , Hydrocortisone/blood , Male , Middle Aged
4.
Endocr Relat Cancer ; 14(4): 935-56, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18045948

ABSTRACT

Pheochromocytomas (PHEOs) are rare neoplasms that produce catecholamines and usually arise from the adrenal medulla and are considered to be an adrenal paraganglioma (PGL). Closely related tumors of extraadrenal sympathetic and parasympathetic paraganglia are classified as extraadrenal PGLs. Most PHEOs are sporadic, but a significant percentage (approximately 25%) may be found in patients with germline mutations of genes predisposing to the development of von Hippel-Lindau disease, neurofibromatosis 1, multiple endocrine neoplasia type 1 (MEN1) and 2 (MEN2), and the PGL/PHEOs syndrome, based on the described mutations of the genes for succinate dehydrogenase subunit D (SDHD), B (SDHB), and C (SDHC). As one out of four PHEOs turns out to be a hereditary clinical entity, screening for genetic alterations is important, as it provides useful information for a rational diagnostic approach and management. This review discusses the genetics, the pathophysiology of hypertension, the clinical picture, the biochemical and imaging diagnosis, and the preferred therapeutic approach for PGLs/PHEOs. Furthermore, it emphasizes the need for genetic testing in cases with apparently sporadic PHEOs.


Subject(s)
Adrenal Gland Neoplasms/genetics , Adrenal Gland Neoplasms/therapy , Pheochromocytoma/genetics , Pheochromocytoma/therapy , Adrenal Gland Neoplasms/epidemiology , Adrenal Medulla/pathology , Adult , Age of Onset , Aged , Child , Chromogranin A/blood , Chromogranin A/genetics , Genetic Predisposition to Disease , Humans , Multiple Endocrine Neoplasia Type 2a/genetics , Paraganglioma/genetics , Pheochromocytoma/epidemiology , Prevalence
5.
Ann Hematol ; 86(1): 23-30, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17013645

ABSTRACT

Osteoporosis has emerged as an important cause of morbidity in patients with thalassemia major. Studies regarding the efficacy of bisphosphonates in thalassemia-induced osteoporosis have yielded conflicting results. We performed this prospective study to evaluate the efficacy of zoledronic acid in osteoporotic patients with thalassemia major. Patients, 29, were given 1 mg zoledronic acid intravenously every 3 months for a total of four doses. Twenty age- and sex-matched healthy blood donors served as controls. Before each infusion and 3 months after the last infusion, we determined serum levels of osteoprotegerin (OPG), N-terminal cross-linking telopeptide of type I collagen (NTX), osteocalcin (OC) and insulin-like growth factor 1 (IGF-1). Bone mineral density (BMD) of the lumbar spine was measured at baseline and after the treatment's completion. At baseline, OPG did not differ significantly between patients and controls (p=0.2), NTX were higher in patients although not significantly (p=0.139), whereas, OC levels were significantly higher and IGF-1 levels significantly lower in patients than in controls (p<0.001 and p<0.006, respectively). Zoledronic acid administration resulted in a significant decrease in NTX, OC and IGF-1 (p<0.05, p<0.001 and p<0.05, respectively) and in a significant increase in OPG and BMD (p<0.05 for both comparisons). The change in NTX, osteocalcin and IGF-1 became significant as early as 3 months after the first administration of zoledronic acid, while the change in OPG reached significance only after three infusions. Our study supports the effectiveness of bisphosphonates in the treatment of thalassemia-induced osteoporosis.


Subject(s)
Bone Density/drug effects , Bone and Bones/metabolism , Diphosphonates/pharmacology , Diphosphonates/therapeutic use , Imidazoles/pharmacology , Imidazoles/therapeutic use , Osteoporosis/drug therapy , Osteoporosis/etiology , beta-Thalassemia/complications , Adult , Biomarkers/analysis , Biomarkers/blood , Bone Density Conservation Agents/pharmacology , Bone Density Conservation Agents/therapeutic use , Bone and Bones/drug effects , Collagen Type I/blood , Female , Humans , Insulin-Like Growth Factor I/analysis , Male , Osteocalcin/blood , Osteoprotegerin/blood , Peptides/blood , Treatment Outcome , Zoledronic Acid
7.
Eur J Endocrinol ; 152(4): 501-13, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15817904

ABSTRACT

Gonadal function is significantly affected in many acute and chronic systemic diseases. As the function of the testes and the ovaries is determined by the integrity of the hypothalamic-pituitary-gonadal axis, it is obvious that a systemic disease may affect one or more levels of the axis in such a manner that the gonadal dysfunction may have various clinical and laboratory manifestations. In this brief review, the most common disturbances seen in the main systemic diseases will be discussed.


Subject(s)
Chronic Disease , Ovary/physiopathology , Testis/physiopathology , Cardiovascular Diseases/physiopathology , Celiac Disease/physiopathology , Female , Humans , Kidney Diseases/physiopathology , Kidney Failure, Chronic/physiopathology , Liver Cirrhosis, Alcoholic/physiopathology , Liver Diseases/physiopathology , Male , Metabolic Syndrome/physiopathology , Rheumatic Diseases/physiopathology , Testosterone/physiology
8.
Ann Hematol ; 84(5): 343-6, 2005 May.
Article in English | MEDLINE | ID: mdl-15580501

ABSTRACT

Tumor lysis syndrome is characterized by multiple metabolic derangements resulting from the release of intracellular components into the bloodstream due to abrupt malignant cell death, spontaneously or following antineoplastic therapy. The syndrome is characterized by hyperkalemia, hyperuricemia, hyperphosphatemia, and hypocalcemia, while deposition of uric acid and calcium phosphate crystals may result in acute renal failure, which is often exacerbated by concomitant intravascular volume depletion. A case of tumor lysis syndrome complicated by acute renal failure in a patient with non-Hodgkin's lymphoma is reported and the pathophysiology, the clinical features, and the treatment options are discussed.


Subject(s)
Acute Kidney Injury/physiopathology , Lymphoma, Non-Hodgkin , Tumor Lysis Syndrome/complications , Tumor Lysis Syndrome/physiopathology , Acute Kidney Injury/etiology , Acute Kidney Injury/therapy , Adult , Humans , Hyperkalemia/physiopathology , Hyperuricemia/physiopathology , Lymphoma, Non-Hodgkin/complications , Lymphoma, Non-Hodgkin/drug therapy , Male , Tumor Lysis Syndrome/etiology
SELECTION OF CITATIONS
SEARCH DETAIL
...